Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biodetection & Biosensors 2017

Karen Kempsell's Biography

Karen Kempsell, Senior Project Team Leader, Public Health England

Dr Karen Kempsell is an established senior scientist in the areas of microbial genetics & pathogenesis, immunopathology and diagnostics. She has an established track record in academic and industrial R&D and twenty three years of experience in the translational research and development area. She is currently the principle investigator/scientific lead of the diagnostics section of the Technology Development group at Public Health England Porton. She has extensive experience in microbiology, clinical infectious diseases, immunopathology, molecular and systems biology, bioinformatics, molecular and serological assay development and commercial diagnostic assay development and validation. She is invited speaker at scientific conferences on development of biomarker-based diagnostics. She manages external collaborations and relationships with key customers and stakeholders. She was the principle investigator on biomarker development programmes which led to patents for diagnostic biomarkers for human tuberculosis and sepsis.

Karen Kempsell Image

Host Biomarker Detection as Diagnostic Indicators of Infection

Wednesday, 11 October 2017 at 17:15

Add to Calendar ▼2017-10-11 17:15:002017-10-11 18:15:00Europe/LondonHost Biomarker Detection as Diagnostic Indicators of InfectionBiodetection and Biosensors 2017 in Murray Edwards College, Cambridge, UKMurray Edwards College, Cambridge,

Host Biomarkers have been used in diagnosis of disease and other conditions for many decades e.g. blood gases, creatinine, CRP, PCT. Clinical diagnoses already rely heavily on these for patient disease management and informing treatment and care pathways. There is a historic precedent for their use e.g. Lateral flow devices (LFDs) e.g. pregnancy test i.e. hCG. Detection of these markers are useful as diagnostic tools, particularly in incidences where infections are hard to diagnose e.g. extra-pulmonary Tuberculosis. The market for biomarker-based biosensor devices is considerable and interest in further diagnostic opportunities is mounting. Here we present evidence to support the use of biomarkers for disease diagnosis and outline translational pipelines and platforms and issues with route to market, particularly for new Tuberculosis diagnostics.

Add to Calendar ▼2017-10-10 00:00:002017-10-11 00:00:00Europe/LondonBiodetection and Biosensors 2017Biodetection and Biosensors 2017 in Murray Edwards College, Cambridge, UKMurray Edwards College, Cambridge,